» Articles » PMID: 11241047

Protein-sensitive and Fasting Hypoglycemia in Children with the Hyperinsulinism/hyperammonemia Syndrome

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2001 Mar 10
PMID 11241047
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Because the hyperinsulinism/hyperammonemia (HI/HA) syndrome is associated with gain of function mutations in the leucine-stimulated insulin secretion pathway, we examined whether protein feeding or fasting was responsible for hypoglycemia in affected patients.

Study Design: Patients with HI/HA (8 children and 6 adults) were studied. All had dominantly expressed mutations of glutamate dehydrogenase and plasma concentrations of ammonium that were 2 to 5 times normal. The responses to a 24-hour fasting test were determined in 7 patients. Responses to a 1.5 gm/kg oral protein tolerance test in 12 patients were compared with responses of 5 control subjects.

Results: The median age at onset of hypoglycemia in the 14 patients was 9 months; diagnosis was delayed beyond age 2 years in 6 patients, and 4 were not given a diagnosis until adulthood. Fasting tests revealed unequivocal evidence of hyperinsulinism in only 1 of 7 patients. Three did not develop hypoglycemia until 12 to 24 hours of fasting; however, all 7 demonstrated inappropriate glycemic responses to glucagon that were characteristic of hyperinsulinism. In response to oral protein, all 12 patients with HI/HA showed a fall in blood glucose compared with none of 5 control subjects. Insulin responses to protein loading were similar in the patients with HI/HA and control subjects.

Conclusion: The postprandial blood glucose response to a protein meal is more sensitive than prolonged fasting for detecting hypoglycemia in the HI/HA syndrome.

Citing Articles

Genotype-histotype-phenotype correlations in hyperinsulinemic hypoglycemia.

Larsen A, Brusgaard K, Christesen H, Detlefsen S Histol Histopathol. 2024; 39(7):817-844.

PMID: 38305063 DOI: 10.14670/HH-18-709.


Standardised practices in the networked management of congenital hyperinsulinism: a UK national collaborative consensus.

Shaikh M, Lucas-Herald A, Dastamani A, Estebanez M, Senniappan S, Abid N Front Endocrinol (Lausanne). 2023; 14:1231043.

PMID: 38027197 PMC: 10646160. DOI: 10.3389/fendo.2023.1231043.


International Guidelines for the Diagnosis and Management of Hyperinsulinism.

De Leon D, Arnoux J, Banerjee I, Bergada I, Bhatti T, Conwell L Horm Res Paediatr. 2023; 97(3):279-298.

PMID: 37454648 PMC: 11124746. DOI: 10.1159/000531766.


Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.

Peterson S, Juliana C, Hu C, Chai J, Holliday C, Chan K Diabetes. 2023; 72(9):1320-1329.

PMID: 37358194 PMC: 10450825. DOI: 10.2337/db22-1039.


A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism.

Juliana C, Chai J, Arroyo P, Rico-Bautista E, Betz S, De Leon D J Biol Chem. 2023; 299(6):104816.

PMID: 37178920 PMC: 10318504. DOI: 10.1016/j.jbc.2023.104816.